Read the Journal "suPAR News" No. 2, 2019 - with lots of interesting articles and interviews from around Europe!

suPARnostic® will now be available for clinical decision making in the University Hospital of Montpellier, France.
It will be the first hospital in the world to run suPARnostic® TurbiLatex at the Roche cobas 8000 system.

ViroGates and QIAGEN announces a partnership to launch suPARnostic® Quick Triage on QIAGEN’s automated Lateral Flow (aLF) platform.

ViroGates is expanding and has employed yet another two employees; new Global Partner Director and new CFO.

New abstract published in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine;

"Availability of suPAR in emergency departments may improve risk stratification: A secondary analysis of the TRIAGE III trial" by Schultz M et al.

Read the new Journal "suPAR News" No.1, 2019 with 10 interesting articles and interviews from around Europe!

Meet us at the 18th International Conference on Emergency Medicine, ICEM 2019, on June 12 -15 in Seoul, Korea and see the suPAR presentations.

Meet us at 51. Gemeinsame Jahrestagung DGIIN/ÖGIAIN on June 12-14 in Berlin, Germany.

Meet us at 2nd Annual Congress on Emergency Medicine and Acute Care on June 10-11 in Helsinki, Finland.

Meet us at XXXI Congreso Nacional SEMES 2019 on June 5-7 in Girona, Spain, and see the suPAR Posters from the hospitals Txagorritxu and Villarrobledo.

Also participate in the round-table discussion on new biomarkers.

Meet us at URGENCES, the national Emergency Conference on June 5-7 in Paris, France.

Meet us at NAKOSDAGENE, the annual Norwegian Emergency Conference on June 5-6 in Bergen, Norway.

New abstract published in Disease Markers;

"Early Discharge from the Emergency Department Based on suPAR Levels: A TRIAGE III Substudy" by Schultz M. et al. 

Amager Hospital, Denmark has entered an agreement with ViroGates for the use of suPARnostic® TurbiLatex in clinical routine practice for the triage and severity assessment of all acute clinical patients in the Emergency Room.

Meet us at DASEM 2019 - Årsmøde Dansk Selskab for Akutmedicin / Danish Society for Emergency Medicine on April 26-27 in Middelfart, Denmark.

New abstract published in Clinical Research in Cardiology;

"Predictive value of suPAR for mortality in patients with suspected myocardial infarction" by Sörensen NA et al.

ViroGates announces that the development and regulatory approval of the suPARnostic® TurbiLatex product for Roche Diagnostics cobas c500 and c700 series has been completed.

Meet us at DINK, Deutscher Interdisziplinärer Notfallmedizin Kongress on March 21-22 in Koblenz, Germany and hear about suPARnostic®

Meet us at Emergency Conference SWEET on March 13-15 in Stockholm, Sweden and hear about suPARnostic®

ViroGates announces that the development and regulatory approval of the suPARnostic® TurbiLatex product for Roche Diagnostics cobas c502 has been completed.

New abstract published in Immunity & Ageing;
"Healthy lifestyles reduce suPAR and mortality in a Danish general population study" by Haupt T.H. et al.

New abstract published in World Journal of Surgery;
"Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments" by Alstrup M et al.

ViroGates is expanding and has welcomed 5 new employees since November 1, 2018.

The ViroGates team now includes 4 new members responsible for Sales and Business Development in Scandinavia, Germany, France and Spain, as well as an International Application Scientist.

New abstract published in BMC Nephrology;

"Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab" by Alachkar N. et al.